Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019: Labor is the most frequent outcome in the European Leukemia Net registry of patients with chronic myeloid leukaemia and pregnancy

14 Jun 2019

Family planning is an important issue for the CML patients of childbearing potential, because they have a normal lifespan in the era of tyrosine kinase inhibitors (TKI).

Management of CML on conceptions and pregnancies is not defined.

Pregnancy cases in CML patients are very rare and the data are scarce.

In total 305 cases of pregnancy in 234 CML female patients from 13 countries worldwide have been collected in the observational retrospective and prospective study of the European Leukemia Net.

The results of this study were presented at the 2019 European Hematology Association (EHA) Annual Meeting.

Most of the pregnancies (77%) ended in labor.

In 71% of pregnancies the patients conceived on TKI treatment and stopped TKIs immediately after pregnancy confirmation.

The rate of congenital abnormalities was 1,7%, no severe or life threatening abnormalities were observed in born children.

Deep molecular response or major molecular response (DMR,MMR) was in 44% of pregnancy cases with known molecular status.

Pregnancy was diagnosed at disease onset in 21% of patients.

Different therapies were used including interferon, imatinib or nilotinib at late pregnancy.

The outline of the patients in the ELN pregnancy registry in terms of conception and pregnancy may be valuable for the development of CML treatment schemes considering the variety of disease status, stage of pregnancy and therapy options.

Source: EHA

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation